BR9806271A - Formulação oral de ciclosporina, e, processo para se obter imunossupressão em um hospedeiro. - Google Patents

Formulação oral de ciclosporina, e, processo para se obter imunossupressão em um hospedeiro.

Info

Publication number
BR9806271A
BR9806271A BR9806271-9A BR9806271A BR9806271A BR 9806271 A BR9806271 A BR 9806271A BR 9806271 A BR9806271 A BR 9806271A BR 9806271 A BR9806271 A BR 9806271A
Authority
BR
Brazil
Prior art keywords
host
cyclosporine
oral formulation
formulations
immunosuppression
Prior art date
Application number
BR9806271-9A
Other languages
English (en)
Inventor
Moo J Cho
Ralph E Levy
Philippe J Pouletty
Original Assignee
Sangstat Medical Corp
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangstat Medical Corp, Univ North Carolina filed Critical Sangstat Medical Corp
Publication of BR9806271A publication Critical patent/BR9806271A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F1/00—Treatment of water, waste water, or sewage
    • C02F1/50—Treatment of water, waste water, or sewage by addition or application of a germicide or by oligodynamic treatment
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F2103/00—Nature of the water, waste water, sewage or sludge to be treated
    • C02F2103/42—Nature of the water, waste water, sewage or sludge to be treated from bathing facilities, e.g. swimming pools
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F2201/00—Apparatus for treatment of water, waste water or sewage
    • C02F2201/008—Mobile apparatus and plants, e.g. mounted on a vehicle
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F2301/00—General aspects of water treatment
    • C02F2301/04—Flow arrangements
    • C02F2301/046—Recirculation with an external loop

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Hydrology & Water Resources (AREA)
  • Environmental & Geological Engineering (AREA)
  • Water Supply & Treatment (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FORMULAçãO ORAL DE CICLOSPORINA, E, PROCESSO PARA SE OBTER IMUNOSSUPRESSãO EM UM HOSPEDEIRO". Formulações orais de ciclosporina melhoradas, que têm alta biodisponibilidade e são capazes de administração tanto na forma líquida quanto na de cápsulas duras, são fornecidas, Nas formulações objeto, a ciclosporina é liberada em um veículo oralmente aceitável, compreendendo pelo menos um solvente de alcanol de 2 a 3 átomos de carbono, em combinação com pelo menos um tensoativo não iónico. As formulações objeto podem ainda compreender pelo menos um co-solvente, onde os co-solventes de interesse incluem ácidos graxos e dióis. As formulações objeto encontram uso na terapia imunossupressiva.
BR9806271-9A 1997-10-23 1998-10-21 Formulação oral de ciclosporina, e, processo para se obter imunossupressão em um hospedeiro. BR9806271A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/956,841 US5962019A (en) 1995-08-25 1997-10-23 Oral cyclosporin formulations
PCT/US1998/022330 WO1999020296A1 (en) 1997-10-23 1998-10-21 Oral cyclosporin formulations

Publications (1)

Publication Number Publication Date
BR9806271A true BR9806271A (pt) 2000-04-04

Family

ID=25498759

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9806271-9A BR9806271A (pt) 1997-10-23 1998-10-21 Formulação oral de ciclosporina, e, processo para se obter imunossupressão em um hospedeiro.

Country Status (20)

Country Link
US (1) US5962019A (pt)
EP (1) EP0956035A1 (pt)
JP (1) JP2000516267A (pt)
KR (1) KR20000069688A (pt)
CN (1) CN1246057A (pt)
AR (1) AR013710A1 (pt)
AU (1) AU9810698A (pt)
BR (1) BR9806271A (pt)
CA (1) CA2275773A1 (pt)
HU (1) HUP0004733A3 (pt)
IL (1) IL130631A0 (pt)
NO (1) NO993096L (pt)
NZ (1) NZ336253A (pt)
PL (1) PL334100A1 (pt)
RU (1) RU2174405C2 (pt)
SK (1) SK97199A3 (pt)
TR (1) TR199901448T1 (pt)
TW (1) TW592707B (pt)
WO (1) WO1999020296A1 (pt)
ZA (1) ZA989684B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858401A (en) * 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
GB2335854B (en) 1997-01-30 2001-04-25 Novartis Ag Oil-free pharmaceutical compositions containing cyclosporin A
DK1154759T3 (da) 1998-12-30 2008-12-08 Dexcel Ltd Dispergerbart koncentrat til indgift af cyclosporin
US6057289A (en) * 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
WO2001021154A2 (en) * 1999-09-21 2001-03-29 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
EP1779859B1 (en) 1999-12-08 2010-06-09 Cyclacel Pharmaceuticals, Inc. Use of depsipeptide and congeners thereof as immunosuppressants in preventing or treating rejection following transplantation and for induction of apoptosis of activated CD4 or CD8 T-cells
US6828302B1 (en) 1999-12-08 2004-12-07 Xcyte Therapies, Inc. Therapeutic uses of depsipeptides and congeners thereof
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6960563B2 (en) * 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
WO2003033527A2 (en) * 2001-10-19 2003-04-24 Isotechnika Inc. Cyclosporine analogue mixtures and their use as immunomodulating agents
WO2003032949A1 (en) * 2001-10-19 2003-04-24 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US7282194B2 (en) * 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
CA2603084A1 (en) * 2005-04-12 2006-10-19 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cyclosporine
US20070015693A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7202209B2 (en) 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US7276476B2 (en) * 2005-07-13 2007-10-02 Allergan, Inc. Cyclosporin compositions
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7501393B2 (en) 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
NZ570802A (en) * 2006-03-02 2012-03-30 Alexion Pharma Inc Prolongation of survival of an allograft by inhibiting complement activity
CN101032620B (zh) * 2007-03-08 2010-05-19 上海凯昭医药科技有限公司 一种环孢素自乳化制剂及其制备方法
JP2010522774A (ja) * 2007-03-30 2010-07-08 フォベア、ファルマスティカル、ソシエテ、アノニム 血管新生眼疾患を治療するための方法
CA2702082A1 (en) * 2007-10-08 2009-04-16 Fovea Pharmaceuticals Sa Aqueous ophthalmic formulations
WO2016194942A1 (ja) * 2015-06-05 2016-12-08 マルホ株式会社 経皮投与用外用剤

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US506219A (en) * 1893-10-10 Steam-cooker
US4117118A (en) * 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
DE2819094A1 (de) * 1977-05-10 1978-11-23 Sandoz Ag Cyclosporin-derivate, ihre verwendung und herstellung
SE445174B (sv) * 1978-03-07 1986-06-09 Sandoz Ag Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans
GB8305693D0 (en) * 1983-03-02 1983-04-07 Scherer Ltd R P Pharmaceutical compositions
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
US5118493A (en) * 1986-05-02 1992-06-02 Brigham And Women's Hospital Composition having reduced nephrotoxocity comprising a fatty acid containing component and cyclosporine
HU205861B (en) * 1986-12-19 1992-07-28 Sandoz Ag Process for producing hydrosole of pharmaceutically effective material
US4792449A (en) * 1987-01-28 1988-12-20 Baxter Travenol Laboratories, Inc. Method for drug administration
US5154930A (en) * 1987-03-05 1992-10-13 The Liposome Company, Inc. Pharmacological agent-lipid solution preparation
KR880012221A (ko) * 1987-04-13 1988-11-26 사노 가즈오 에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물
JP2577049B2 (ja) * 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
HU205010B (en) * 1987-09-15 1992-03-30 Sandoz Ag Process for producing pharmaceutical compositions comprising compounds soluble up to 1 per cent and having medical activity
GB8729153D0 (en) * 1987-12-14 1988-01-27 Efamol Ltd Fatty acid compositions
HU203564B (en) * 1987-12-21 1991-08-28 Sandoz Ag Process for producing new orthorombos cyclosporin without solvatation
EP0327280B1 (en) * 1988-01-29 1992-03-18 Sankyo Company Limited Cyclosporin compositions
HU201567B (en) * 1988-07-21 1990-11-28 Gyogyszerkutato Intezet Process for production of intravenous medical compositions containing cyclosphorin
US5350741A (en) * 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
CH679210A5 (pt) * 1988-10-26 1992-01-15 Sandoz Ag
BE1003009A5 (fr) * 1989-02-09 1991-10-22 Sandoz Sa Nouvelles compositions pharmaceutiques a base de cyclosporines.
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5364632A (en) * 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
WO1991016057A1 (en) * 1990-04-18 1991-10-31 University Of Utah COLONIC-TARGETED ORAL DRUG-DOSAGE FORMS BASED ON CROSSLINKED HYDROGELS CONTAINING AZOBONDS AND EXHIBITING pH-DEPENDENT SWELLING
JPH04253907A (ja) * 1990-05-23 1992-09-09 Green Cross Corp:The 静脈注射用免疫抑制剤
US5393791A (en) * 1990-07-19 1995-02-28 Helena Chemical Company Homogeneous, essentially nonaqueous adjuvant compositions with buffering capability
HU208491B (en) * 1990-11-27 1993-11-29 Gyogyszerkutato Intezet Process for producing oral pharmaceutical composition containing cyclosporin
US5122383A (en) * 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
MX9201782A (es) * 1991-04-19 1992-10-01 Sandoz Ag Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene.
IL102236A0 (en) * 1991-06-27 1993-01-14 Ltt Inst Co Ltd Topical preparations containing cyclosporin
JPH0558906A (ja) * 1991-09-06 1993-03-09 Sankyo Co Ltd シクロスポリン点眼製剤
GB9208712D0 (en) * 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
ES2098739T3 (es) * 1992-05-13 1997-05-01 Sandoz Ltd Composiciones oftalmicas conteniendo una cyclosporin.
IT1260505B (it) * 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
EP1142568A1 (en) * 1992-09-25 2001-10-10 Novartis AG Pharmaceutical compositions containing cyclosporins
CA2161143A1 (en) * 1993-04-20 1994-10-27 Monika Fleck New pharmaceutical preparations comprising cyclosporin for oral administration
CN1077800C (zh) * 1993-07-01 2002-01-16 韩美药品工业株式会社 环孢菌素软胶囊组合物
DE4329503A1 (de) * 1993-09-01 1995-03-02 Galenik Labor Freiburg Gmbh Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa
DE4340781C3 (de) * 1993-11-30 2000-01-27 Novartis Ag Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
KR0146671B1 (ko) * 1994-02-25 1998-08-17 김충환 사이클로스포린-함유 분말 조성물
PT789580E (pt) * 1994-11-03 2002-09-30 Novartis Ag Formulacoes de ciclosporina para administracao oral com composicao simples e alta biodisponibilidade e processo para a sua producao
HU215966B (hu) * 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
KR0167613B1 (ko) * 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
BR9606603A (pt) * 1995-08-25 1997-09-30 Sangstat Medical Corp Formulação de ciclosporina dispersão aquosa de nanopartículas de ciclosporina kit e processo de preparação de dispersão aquosa de partículas de ciclosporina
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
NZ280689A (en) * 1995-12-15 1997-08-22 Bernard Charles Sherma Sherman Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol
AU6461898A (en) * 1997-03-12 1998-09-29 Abbott Laboratories Hydrophilic binary systems for the administration of cyclosporine

Also Published As

Publication number Publication date
TW592707B (en) 2004-06-21
KR20000069688A (ko) 2000-11-25
HUP0004733A2 (hu) 2001-05-28
AU9810698A (en) 1999-05-10
IL130631A0 (en) 2000-06-01
CN1246057A (zh) 2000-03-01
US5962019A (en) 1999-10-05
WO1999020296A1 (en) 1999-04-29
RU2174405C2 (ru) 2001-10-10
CA2275773A1 (en) 1999-04-29
JP2000516267A (ja) 2000-12-05
ZA989684B (en) 1999-04-25
HUP0004733A3 (en) 2001-12-28
NO993096L (no) 1999-08-17
AR013710A1 (es) 2001-01-10
NZ336253A (en) 2001-06-29
SK97199A3 (en) 2004-10-05
EP0956035A1 (en) 1999-11-17
TR199901448T1 (xx) 1999-12-21
PL334100A1 (en) 2000-01-31
NO993096D0 (no) 1999-06-22

Similar Documents

Publication Publication Date Title
BR9806271A (pt) Formulação oral de ciclosporina, e, processo para se obter imunossupressão em um hospedeiro.
FI955091A0 (fi) Parannetut farmaseuttisesti hyväksyttävät seokset, jotka sisältävät alkoholia ja hydrofobista lääkettä
PA8481401A1 (es) 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-carboxiamino
AR001985A1 (es) Formulaciones de ciclosporina oral
EA200300634A1 (ru) Фармацевтическая композиция, содержащая действующее вещество, диспергированное в матрице
PT789580E (pt) Formulacoes de ciclosporina para administracao oral com composicao simples e alta biodisponibilidade e processo para a sua producao
MX9203504A (es) Complejo agente: lipido activo de alta proporcion.
FR2692168B1 (fr) Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères.
GB2314508A (en) Diamide-dicarboxylic acid microspheres
DE69211691D1 (de) Pharmazeutische formulierung und pharmazeutisches verfahren
ES2191862T3 (es) Composicion liquida que comprende un inhibidor de la vih proteasa y un acido graso de c12-c18.
AR012287A1 (es) Preparado de medicamento para la administracion peroral y uso de portadores, especialmente de polietilenglicol-660-12-hidroxiestearato yetanol o 1,2-propilenglicol
UY23864A1 (es) Procedimiento para preparar nuevas composiciones farmaceuticas a base de ciclosporinas
GT199900149A (es) 4-carboxiamino-2-metil -1,2,3,4- tetrahidroquinolinas.
BR9810866A (pt) Composição farmacêutica em uma forma de formulação auto-emulsificante para compostos lipofìlicos
BR9811058A (pt) Formulação auto-emulsificante para compostos lipofìlicos
TR200102861T2 (tr) Uzun zincirli trigliseridler ve lipofilik surfaktantları içeren oral farmasötik kompozisyonlar.
ES2145158T3 (es) Nueva formulacion de emulsion.
CU22836A3 (es) Sistema de gel de nimesulida para uso tópico
KR950007857A (ko) 경구투여용 라파마이신 제제
AR002704A1 (es) 2-(2-n-alcoxifenil)-purin-6-onas 9-sustituidas, procedimiento para su preparacion, composiciones farmaceuticas que las contienen y su uso parapreparar composiciones farmaceuticas.
ES2023148T5 (es) Agente cosmetico, en particular agente hidratante para la proteccion de la piel.
ES2191624T3 (es) Mezclas de tensioactivos usados como agentes humectantes y/o emulsionantes en preparaciones agroquimicas.
DE59813853D1 (de) Flüssige darreichungsformen oxazaphosphorinhaltiger pharmazeutischer produkte
DE59811094D1 (de) Hautschutzzubereitung

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A,7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1886 DE 27/02/2007.